bavisant dihydrochloride hydrate

Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action related to wakefulness and cognition, and it has potential as a treatment for ADHD. In a clinical trial, the mean change from baseline in the total ADHD-RS-IV score at day 42 was -8.8 in the placebo group versus -9.3, -11.2, and -12.2 in the bavisant 1 mg day, 3 mg day, and 10 mg day groups, respectively; however, the change in the 10 mg day group was not statistically superior to placebo (p=0.161). Statistical comparisons of the 1 mg day and 3 mg day groups with placebo based on a step-down closed testing procedure were not performed. Bavisant has completed a phase II ADHD trial, but no results have been reported [1]. Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2. IC50 Value: Target: H3 receptor in vitro.

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Quinacrine is a compound that is commonly used as an anti-protozoal agent. It inhibits voltage-dependent sodium channels (IC50: 3.3 μM） and suppresses aldehyde oxidase (IC50: 3.3 μM). Quinacrine prevents misfolding of prion protein (EC50: 0.3 μM). As an e

BMS-433771 dihydrochloride hydrate is a potent, orally active inhibitor of respiratory syncytial virus (RSV), effective against both group A and B strains with an average EC50 of 20 nM, and is utilized in researching respiratory tract diseases.

Mibefradil dihydrochloride hydrate (Ro 40-5967 dihydrochloride hydrate) is a long-acting calcium channel antagonist and antihypertensive agent with a higher affinity for high-voltage activated (L) calcium channels.

Bavisant (JNJ-310010740) dihydrochloride is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition.

Cefotiam dihydrochloride hydrate (SCE-963), a parenteral cephalosporin antibiotic, exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria [1] [2].